Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

AIMS: Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in the EMPULSE trial (NCT0415775) were evaluated. METHODS AND RESU...

Descripción completa

Detalles Bibliográficos
Autores principales: Biegus, Jan, Voors, Adriaan A, Collins, Sean P, Kosiborod, Mikhail N, Teerlink, John R, Angermann, Christiane E, Tromp, Jasper, Ferreira, Joao Pedro, Nassif, Michael E, Psotka, Mitchell A, Brueckmann, Martina, Salsali, Afshin, Blatchford, Jonathan P, Ponikowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805406/
https://www.ncbi.nlm.nih.gov/pubmed/36254693
http://dx.doi.org/10.1093/eurheartj/ehac530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805406/
https://www.ncbi.nlm.nih.gov/pubmed/36254693
http://dx.doi.org/10.1093/eurheartj/ehac530

Ejemplares similares